After leading Novo Nordisk’s push in obesity, Jørgensen stepping aside as CEO

Lars Fruergaard Jørgensen, the leader who spearheaded Novo Nordisk’s transformation into a dominant player in obesity, is stepping aside as CEO after eight years in which the company’s sales, profits and stock have all nearly tripled.

Jørgensen took the helm of  Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) at the start of 2017, a time when U.S. pricing pressure on insulin and hemophilia products saw the company guide for negative sales and operating profit growth for the first time in its history. ...